SCREENING
GENETIC CONDITIONS
EARLY AND AFFORDABLY

Every life deserves
a better start

Volume icon

Each year, 140 million babies are born —and 7 million will have a genetic disorder. Tragically, most of these conditions go undiagnosed or misdiagnosed due to the limitations of current screening methods, leading to delayed interventions, worse health outcomes, and significant financial burdens for families and healthcare systems.

In the Global North, outdated technologies result in over 400,000 false positives annually, causing unnecessary emotional distress and avoidable costs.

In the Global South, 95 million newborns have no access to genetic screening at all, missing the critical window for early diagnosis and life-saving treatment.

The challenge is clear: we need affordable, accurate, and scalable mass screening solutions — especially in prenatal and newborn care. Early intervention can prevent long-term complications and save up to €500,000 per patient in lifetime healthcare costs.

Meanwhile, the genetic disorder screening and diagnostics market, valued at €30 billion, is expected to double by 2030.

And at the heart of it all: infant mortality, one of the most powerful indicators of a society’s quality of life. Newborn screening is one of the most effective tools we have to improve it.

DISCOVER PHIVEA® > AND THE GMENDEL®TEST >

Key research & technology milestones to date

Latest news

Genetic Disorders

A genetic disorder is a disease caused in whole or in part by a change in the DNA sequence away from the normal sequence.

Genetic disorders can be caused by a mutation in one gene, by mutations in multiple genes, by a combination of gene mutations and environmental factors, or by damage to chromosomes, the structures that carry genes.

Rare diseases